Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 25 of the 51 sources its claims cite were checked for support.

Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant

Open access

Abstract

OBJECTIVE: Melatonin use quintupled in recent decades. The common melatonin receptor 1B gene (MTNR1B) variant increases risk of type 2 diabetes, raising concerns about melatonin’s adverse metabolic effects and highlighting the need for a genotype-based personalized approach. We aimed to comprehensively characterize the actions of melatonin on glucose homeostasis, including first- and second-phase β-cell responsivity to glucose, β-cell negative feedback by exogeneous insulin, insulin sensitivity, and whether such effects are stronger in MTNR1B G-allele risk carriers compared with noncarriers. RESEARCH DESIGN AND METHODS: Twenty-one healthy participants of European ancestry were studied in a randomized, double-blind, placebo-controlled, crossover trial, including 10 MTNR1B risk carriers and 11 noncarriers. Each participant underwent a highly controlled 5-day laboratory protocol, during which they received 5 mg oral melatonin or placebo in randomized order on two nonconsecutive days. Glycemic dynamics were assessed using insulin-modified intravenous glucose tolerance tests with minimal-model analysis. RESULTS: Melatonin worsened glucose tolerance and reduced early C-peptide responses in risk allele carriers (vs. placebo: 11.7% [95% CI 1.0–22.3] and −19.2% [−33.9 to −1.2], respectively; Padj < 0.05) but not in noncarriers. In carriers, impairments stemmed from a 40% (−52.4 to −24.3; Padj = 0.0003) suppression of glucose-stimulated first-phase β-cell responsivity, along with a slower insulin-induced decline in second-phase insulin secretion rate (64.3% [23.1–119.2]; Padj = 0.001). In carriers, melatonin also prevented exogenous insulin-induced hypoglycemia compared with placebo (zero vs. seven events, P = 0.001), but not in noncarriers. CONCLUSIONS: These findings identify blunted β-cell responsivity to glucose and dysregulated insulin negative feedback as key mechanisms linking melatonin signaling to diabetes risk.

Overview

CoChat Summary

TL;DR

In a randomized, double-blind, placebo-controlled crossover trial of 21 healthy European-ancestry adults, 5 mg oral melatonin acutely worsened glucose tolerance and early insulin/C-peptide responses only in *MTNR1B* risk allele carriers. The impairments were linked to reduced first-phase β-cell responsivity to glucose and slower insulin-induced decline in second-phase insulin secretion rate, with fewer exogenous insulin-induced hypoglycemic events in carriers.

Key findings

  • In *MTNR1B* risk allele carriers, melatonin increased 3-h glucose iAUC by 11.7% (95% CI 1.0–22.3; Padj = 0.03) versus placebo; noncarriers showed no significant change (−5.0% [−14.1 to 4.1], Padj = 0.35).
  • Early 20-min C-peptide iAUC decreased by 19.2% (−33.9 to −1.2; Padj = 0.04) in carriers, with a 25.2% insulin iAUC decrease (−44.9 to 1.4; Padj = 0.06); noncarriers had no significant changes.
  • First-phase β-cell responsivity to glucose (Φ1) was reduced by melatonin overall (−25.6% [−35.2 to −14.6]; P = 0.0003), driven by carriers (−39.9% [−52.4 to −24.3]; Padj < 0.0001) versus noncarriers (−7.9% [−26.1 to 14.9]; Padj = 0.62).
  • In carriers, melatonin prolonged the half-time of second-phase insulin secretion rate decline by 64.3% (23.1–119.2; Padj = 0.001) and prevented exogenous insulin-induced level 1 hypoglycemia (zero vs. seven events, P = 0.001); noncarriers showed no significant T1/2 change (13.3% [−34.1 to 94.5], Padj = 0.41) or hypoglycemia difference (two vs. five events, P = 0.20).

Methods

  • Randomized, double-blind, placebo-controlled crossover trial: 21 healthy nonsmoking European-ancestry adults aged 21–55 years, BMI 20–35 kg/m², including 10 *MTNR1B* risk carriers and 11 noncarriers; 5-day in-laboratory protocol with fixed sleep/wake schedule, 5 mg oral melatonin or placebo on two nonconsecutive days, and 48-h washout.
  • Insulin-modified frequently sampled intravenous glucose tolerance tests (FSIGT) with minimal-model analysis estimated insulin sensitivity, glucose effectiveness, β-cell responsivity indices (Φ1, Φ2, Φt), insulin secretory rate, disposition index, insulin clearance, and hepatic insulin extraction.
  • Mixed-model ANOVA on log-transformed data with treatment, carrier status, and interaction terms; Šídák adjustment for multiple comparisons; χ² test for hypoglycemic events (<70 mg/dL).

Limitations

  • Stated: modest study duration and sample size; enrollment restricted to adults of European ancestry to reduce uncertainty and variability, limiting generalizability; participants were healthy individuals without diabetes, so the study did not test long-term melatonin administration or effects in patient populations.
  • Stated: the study aimed to test acute interaction effects of melatonin and *MTNR1B* genotype, not whether long-term melatonin causes type 2 diabetes or improves glucose control.
  • Evident from the text: the small sample (21 total; 10 carriers, 11 noncarriers) limits precision and subgroup analyses; findings may not generalize to other ancestries, diabetes populations, or chronic dosing; the afternoon FSIGT timing may differ from prior morning studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/dc26-0164

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

16 Valid · 2 Not valid · 13 Not checked · 69 Own results and interpretations

30 more claims · 1 with their cited sources checked

Create a free account to see all 100 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 32
  • It may state two separate claims as one. 44
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Phan L , JinY, ZhangH, . ALFA: Allele Frequency Aggregator, 2020. Accessed 22 January 2026. Available from www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/

Metadata

Authors
Qian, J., Stefanovski, D., Andersen, P. A. K., Vujovic, N., Kelly, L., Lepson, J., Nguyen, H., Byrne, S., Wang, W., Mandrup-Poulsen, T., Adler, G., Garaulet, M., Saxena, R., & Scheer, F. A. J. L.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Pennsylvania (US)
  • Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital 1 , Boston, MA
  • University of Copenhagen (DK)
  • Harvard University (US)
  • Broad Institute (US)
Corresponding author
Qian, Jingyi
Venue
Diabetes Care
Published
2026-06-25
Volume
49
Issue
8
Pages
1498-1506
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W7165915750
Cited by
0
References
31
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Brigham and Women's Hospital (R01 DK102696, R01 HL153969, R01 HL164454, R01 HL167746)
  • ADA (1-17-PDF-103, K99 HL 148500, R01 DK102696)
  • NIDDK (R01 DK102696)
  • Independent Research Fund Denmark (8020-00359B)
  • CTSA (UL1RR025758)
  • Harvard University
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
melatonin, MTNR1B, type 2 diabetes risk, glucose tolerance, first-phase insulin secretion, insulin sensitivity, insulin-induced hypoglycemia, C-peptide, glucose homeostasis
MeSH terms
Insulin Secretion, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucose Tolerance Test, Humans, Insulin, Male, Melatonin, Middle Aged, Cross-Over Studies, Receptor, Melatonin, MT2, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. https://app.cochat.ai/papers/10.2337/dc26-0164
The paper
Qian, J., Stefanovski, D., Andersen, P. A. K., Vujovic, N., Kelly, L., Lepson, J., Nguyen, H., Byrne, S., Wang, W., Mandrup-Poulsen, T., Adler, G., Garaulet, M., Saxena, R., & Scheer, F. A. J. L. (2026). Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care. https://doi.org/10.2337/dc26-0164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.